Parkinson's disease (PD) is the second most common neurodegenerative disease. Oxidative stress and mitochondrial dysfunction play key roles in PD pathophysiology. Animal studies have shown that photobiomodulation (PBM) can enhance mitochondrial function and promote the production of adenosine triphosphate, thereby alleviating PD symptoms. However, this process leads to increased production of reactive oxygen species (ROS). Molecular hydrogen (H2) is a potent and possible therapeutic antioxidant that can mitigate the effects of ROS. PBM targeting the brain stem promotes neuronal activity, and the accompanying H2 scavenges additional ROS produced by PBM. Results :UPDRS scores decreased significantly from the first week, and this improvement was sustained until the end of treatment. In addition, no adverse events were recorded. One week after discontinuation of treatment, UPDRS scores increased slightly but remained significantly improved from baseline. Conclusion :PBM+H2 treatment is safe and reduces the severity of the disease.